LC-MS-based Diagnostic Assay

The research on "LC-MS-based Diagnostic Assays" focuses on developing innovative in vitro and companion diagnostic technologies for direct clinical application using liquid chromatography-mass spectrometry (LC-MS). This cutting-edge approach enables the analysis of multiple biomarkers simultaneously, generating comprehensive OMICS big data. By applying artificial intelligence to this data, the research aims to overcome individual patient variabilities, disease complexities, and environmental factors, paving the way for highly personalized precision medicine. Recognizing LC-MS as a pivotal technology in the future of precision healthcare, the team is committed to creating LC-MS-based medical technologies that surpass the performance of existing analytical methods. To facilitate entry into both domestic and international clinical diagnostics markets, the research pursues new medical technology certifications and Clinical Laboratory Improvement Amendments (CLIA) accreditation, ensuring that these advanced diagnostic tools can be effectively implemented in real-world healthcare settings, ultimately revolutionizing patient care and treatment outcomes.